James E. Shaw

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · Journal of Clinical Oncology · 2014 · 406 citations

Medicine, Oncology, Pharmacotherapy +14

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Alan P. Venook, Donna Niedzwiecki, Federico Innocenti et al. · Journal of Clinical Oncology · 2016 · 333 citations

Medicine, Oncology, Surgery +16

The role of oxidative stress in the prolonged inhibitory effect of ultrafine carbon black on epithelial cell function

Vicki Stone, James E. Shaw, David M. Brown et al. · Toxicology in Vitro · 1998 · 219 citations

Life Sciences, Biochemistry, Cell Biology +17

Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication

Brenda M. Colby, James E. Shaw, Gertrude B. Elion et al. · Journal of Virology · 1980 · 218 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +15

Correlated Fluorescence-Atomic Force Microscopy of Membrane Domains: Structure of Fluorescence Probes Determines Lipid Localization

James E. Shaw, Richard M. Epand, Zaiguo Li et al. · Biophysical Journal · 2005 · 181 citations · Full text

Natural Sciences, Biochemistry, Biophysics +16